Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhASB in Patients With MPS VI
NCT00048711Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Mar 2002
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of galsulfase in mucopolysaccharidosis type VI, sponsored by BioMarin Pharmaceutical. Primary endpoints: 12-minute walk test at 144 weeks and urinary glycoaminoglycan levels at 12 weeks. Started Mar 2002; status: completed.
02
Drugs
galsulfase
03
Conditions
mucopolysaccharidosis type VI
Beyond the preview
Go deeper on NCT00048711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048711.